Rai- refractory papillary thyroid carcinoma: one of the first patients to use lenvatinib in the country, case report

Introduction: Thyroid cancer represents the most common tumor in women, approximately 10 to 20% of differentiated thyroid carcinomas (DTC) develop metastases, failure in treatment with iodine occurs in 50% of cases.The advent of Tyrosine Kinase Inhibitors (TKIs) has undergone a radical change in the pattern of treatment for DTC.Objectives: To report a case of Rai-refractory metastatic DTC, whose patient is one of the first to use lenvatinib in the country.Conclusions: With treatment, a patient under surveillance for metastatic diseases and multiple treatment line, exhibited response rates consistent with literary data, decreasing biochemical markers and manageable toxicity.